Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
title
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Creator
Coutard, Bruno
Piorkowski, Géraldine
Touret, Franck
Nougairède, Antoine
De 3 Lamballerie, Xavier
»more»
source
BioRxiv
abstract
Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we used a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determine its pharmacokinetics. When treatment was initiated before or simultaneously to infection, favipiravir had a strong dose effect, leading to dramatic reduction of infectious titers in lungs and clinical alleviation of the disease. Antiviral effect of favipiravir correlated with incorporation of a large number of mutations into viral genomes and decrease of viral infectivity. The antiviral efficacy observed in this study was achieved with plasma drug exposure comparable with those previously found during human clinical trials and was associated with weight losses in animals. Thereby, pharmacokinetic and tolerance studies are required to determine whether similar effects can be safely achieved in humans.
has issue date
2020-07-17
(
xsd:dateTime
)
bibo:doi
10.1101/2020.07.07.191775
has license
biorxiv
sha1sum (hex)
38cd7a8a09785296d9a532f70a9b4ccef16bc408
schema:url
https://doi.org/10.1101/2020.07.07.191775
resource representing a document's title
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
schema:publication
bioRxiv
resource representing a document's body
covid:38cd7a8a09785296d9a532f70a9b4ccef16bc408#body_text
is
schema:about
of
named entity 'large number'
named entity 'effects'
named entity 'pharmacokinetic'
named entity 'mutations'
named entity 'hamster'
»more»
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 6
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software